Inhibition of Colony-Stimulating Factor-1 Receptor Enhances the Efficacy of Radiotherapy and Reduces Immune Suppression in Glioblastoma

Overview

Journal In Vivo

Specialty Oncology

Date 2021 Jan 6

PMID 33402457

Citations 23

Authors

Muayad F Almahariq

Thomas J Quinn

Pravin Kesarwani

Shiva Kant

C Ryan Miller

Prakash Chinnaiyan

Affiliations

Soon will be listed here.

Abstract

Aim: To use inhibition of colony-stimulating factor-1 receptor (CSF-1R) to target tumor-associated macrophages (TAMs) and improve the efficacy of radiotherapy in glioblastoma (GBM).

Materials And Methods: The CSF-1R inhibitor BLZ-945 was used to examine the impact of CSF-1R inhibition on M2 polarization in vitro. Using an orthotopic, immunocompetent GBM model, mice were treated with vehicle, RT, BLZ-945, or RT plus BLZ-945.

Results: BLZ-945 reduced M2 polarization in vitro. BLZ-945 alone did not improve median overall survival (mOS=29 days) compared to control mice (mOS=27 days). RT improved survival (mOS=45 days; p=0.02), while RT plus BLZ-945 led to the longest survival (mOS=not reached; p=0.005). Resected tumors had a relatively large population of M2 TAMs in GBM at baseline, which was increased in response to RT. BLZ-945 reduced RT-induced M2 infiltration.

Conclusion: Inhibition of CSF-1R improved response to RT in the treatment of GBM and may represent a promising strategy to improve RT-induced antitumor immune responses.

Citing Articles

Tumor-associated macrophages within the immunological milieu: An emerging focal point for therapeutic intervention.

Shao Y, Han S, Hou Z, Yang C, Zhao Y Heliyon. 2024; 10(17):e36839.

PMID: 39281573 PMC: 11401039. DOI: 10.1016/j.heliyon.2024.e36839.

Shifting cold to hot tumors by nanoparticle-loaded drugs and products.

Ahmad I, Atiyah Altameemi K, Hani M, Ali A, Shareef H, Hassan Z Clin Transl Oncol. 2024; 27(1):42-69.

PMID: 38922537 DOI: 10.1007/s12094-024-03577-3.

Non-targeted effects of radiation therapy for glioblastoma.

Lerouge L, Ruch A, Pierson J, Thomas N, Barberi-Heyob M Heliyon. 2024; 10(10):e30813.

PMID: 38778925 PMC: 11109805. DOI: 10.1016/j.heliyon.2024.e30813.

Role of Tumor-Associated Macrophages in Cervical Cancer: Integrating Classical Perspectives with Recent Technological Advances.

Choi Y, Lee D, Kim N, Seo I, Park N, Chong G Life (Basel). 2024; 14(4).

PMID: 38672714 PMC: 11051155. DOI: 10.3390/life14040443.

Identification of Key Molecular Pathways and Associated Genes as Targets to Overcome Radiotherapy Resistance Using a Combination of Radiotherapy and Immunotherapy in Glioma Patients.

Zhang T, Zhang Q, He X, Lu Y, Shao A, Sun X Int J Mol Sci. 2024; 25(5).

PMID: 38474320 PMC: 10931693. DOI: 10.3390/ijms25053076.

References

Jackson C, Choi J, Lim M . Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019; 20(9):1100-1109. DOI: 10.1038/s41590-019-0433-y. View

Poh A, Ernst M . Targeting Macrophages in Cancer: From Bench to Bedside. Front Oncol. 2018; 8:49. PMC: 5858529. DOI: 10.3389/fonc.2018.00049. View

Reardon D, Brandes A, Omuro A, Mulholland P, Lim M, Wick A . Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(7):1003-1010. PMC: 7243167. DOI: 10.1001/jamaoncol.2020.1024. View

Brocard E, Oizel K, Lalier L, Pecqueur C, Paris F, Vallette F . Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling. Oncotarget. 2015; 6(9):6840-9. PMC: 4466653. DOI: 10.18632/oncotarget.3160. View

Kesarwani P, Prabhu A, Kant S, Chinnaiyan P . Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma. Cancer Immunol Immunother. 2019; 68(7):1107-1120. PMC: 6586493. DOI: 10.1007/s00262-019-02347-3. View

Butowski N, Colman H, de Groot J, Omuro A, Nayak L, Wen P . Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2015; 18(4):557-64. PMC: 4799682. DOI: 10.1093/neuonc/nov245. View

Liu S, Sun X, Luo J, Zhu H, Yang X, Guo Q . Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res. 2016; 5(11):3276-85. PMC: 4697676. View

Schmid R, Simon J, Vitucci M, McNeill R, Bash R, Werneke A . Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. Neuro Oncol. 2016; 18(7):962-73. PMC: 4896545. DOI: 10.1093/neuonc/nov321. View

Caccese M, Indraccolo S, Zagonel V, Lombardi G . PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review. Crit Rev Oncol Hematol. 2019; 135:128-134. DOI: 10.1016/j.critrevonc.2018.12.002. View

10.

Roszer T . Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. Mediators Inflamm. 2015; 2015:816460. PMC: 4452191. DOI: 10.1155/2015/816460. View

11.

Ladomersky E, Zhai L, Lenzen A, Lauing K, Qian J, Scholtens D . IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018; 24(11):2559-2573. PMC: 5984675. DOI: 10.1158/1078-0432.CCR-17-3573. View

12.

Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R . Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res. 2011; 17(13):4296-308. DOI: 10.1158/1078-0432.CCR-10-2557. View

13.

Seifert L, Werba G, Tiwari S, Ly N, Nguy S, Alothman S . Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology. 2016; 150(7):1659-1672.e5. PMC: 4909514. DOI: 10.1053/j.gastro.2016.02.070. View

14.

Tabatabaei P, Visse E, Bergstrom P, Brannstrom T, Siesjo P, Bergenheim A . Radiotherapy induces an immediate inflammatory reaction in malignant glioma: a clinical microdialysis study. J Neurooncol. 2016; 131(1):83-92. PMC: 5258803. DOI: 10.1007/s11060-016-2271-1. View

15.

Quail D, Bowman R, Akkari L, Quick M, Schuhmacher A, Huse J . The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016; 352(6288):aad3018. PMC: 5450629. DOI: 10.1126/science.aad3018. View

16.

Mantovani A, Biswas S, Galdiero M, Sica A, Locati M . Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2012; 229(2):176-85. DOI: 10.1002/path.4133. View

17.

Genard G, Lucas S, Michiels C . Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Front Immunol. 2017; 8:828. PMC: 5509958. DOI: 10.3389/fimmu.2017.00828. View

18.

Wilson T, Hanna A, Recknagel J, Pruetz B, Baschnagel A, Wilson G . Prognostic significance of MTOR expression in HPV positive and negative head and neck cancers treated by chemoradiation. Head Neck. 2019; 42(2):153-162. DOI: 10.1002/hed.25983. View

19.

Kesarwani P, Prabhu A, Kant S, Kumar P, Graham S, Buelow K . Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma. Clin Cancer Res. 2018; 24(15):3632-3643. PMC: 6591719. DOI: 10.1158/1078-0432.CCR-18-0041. View

20.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L . Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017; 32(1):42-56.e6. PMC: 5599156. DOI: 10.1016/j.ccell.2017.06.003. View